Pre-clinical study of 21 approved drugs in the mdx mouse

Neuromuscular Disorders

Volumn 21, Issue 5, 2011, Pages 313-327

  Carre Pierrat, Maïté ^a   Lafoux, Aude ^b   Tanniou, Guillaume ^c   Chambonnier, Lucie ^a   Divet, Alexandra ^b   Fougerousse, Francoise ^c   Huchet Cadiou, Corinne ^b   Ségalat, Laurent ^a  

^a CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c GÉNÉTHON   (France)

Author keywords

Antidepressants; Duchenne muscular dystrophy; Dystrophin; Mdx Mouse; Nematode; Tricyclics

Indexed keywords

AMITRIPTYLINE; CARISOPRODOL; CHLORMEZANONE; CHLORPROTHIXENE; CLOXACILLIN; CYCLOBENZAPRINE; DESIPRAMINE; DYSTROPHIN; FLUOXETINE; HYDRALAZINE; IMIPRAMINE; MEXILETINE; NIFEDIPINE; NITROFURANTOIN; NOSCAPINE; ORPHENADRINE; PENTOXIFYLLINE; PREDNISONE; TOLAZAMIDE; TRIMIPRAMINE; VINBURNINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FAST MUSCLE; FEMALE; MALE; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL;

EID: 79955484144     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2011.01.005     Document Type: Article

References (48)

1. Dubowitz V. What is muscular dystrophy? Forty years of progressive ignorance. J R Coll Physicians Lond 2000, 34:464-468.
2. Blake D.J., Weir A., Newey S.E., Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002, 82:291-329.
3. Deconinck N., Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007, 36:1-7.
4. Khurana T.S., Davies K.E. Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov 2003, 2:379-390.
5. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007, 36:424-435.
6. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; CD003725.
7. Trollet C., Athanasopoulos T., Popplewell L., Malerba A., Dickson G. Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opin Biol Ther 2009, 9:849-866.
8. Wang Z., Chamberlain J.S., Tapscott S.J., Storb R. Gene therapy in large animal models of muscular dystrophy. ILAR J 2009, 50:187-198.
9. Gaud A., Simon J.M., Witzel T., Carre-Pierrat M., Wermuth C.G., Segalat L. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul Disord 2004, 14:365-370.
10. Carre-Pierrat M., Mariol M.C., Chambonnier L., et al. Blocking of striated muscle degeneration by serotonin in C. elegans. J Muscle Res Cell Motil 2006, 27:253-258.
11. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
12. Raymackers J.M., Debaix H., Colson-Van Schoor M., et al. Consequence of parvalbumin deficiency in the mdx mouse: histological, biochemical and mechanical phenotype of a new double mutant. Neuromuscul Disord 2003, 13:376-387.
13. Auda-Boucher G., Rouaud T., Lafoux A., et al. Fetal muscle-derived cells can repair dystrophic muscles in mdx mice. Exp Cell Res 2007, 313:997-1007.
14. Divet A., Huchet-Cadiou C. Sarcoplasmic reticulum function in slow- and fast-twitch skeletal muscles from mdx mice. Pflugers Arch 2002, 444:634-643.
15. 2 injuries in diaphragm muscle from mdx mice. J Pharmacol Exp Ther 2006, 318:1359-1367.
16. Huchet C., Leoty C. Effects of cyclopiazonic acid on Ca(2+)-activated tension production in skinned skeletal muscle fibres of the ferret. Eur J Pharmacol 1993, 241:41-46.
17. Williams D.A., Head S.I., Lynch G.S., Stephenson D.G. Contractile properties of skinned muscle fibres from young and adult normal and dystrophic (mdx) mice. J Physiol 1993, 460:51-67.
18. Godt R.E., Nosek T.M. Changes of intracellular milieu with fatigue or hypoxia depress contraction of skinned rabbit skeletal and cardiac muscle. J Physiol 1989, 412:155-180.
19. Carlson C.G., Makiejus R.V. A noninvasive procedure to detect muscle weakness in the mdx mouse. Muscle Nerve 1990, 13:480-484.
20. Marechal G., Beckers-Bleukx G. Effect of nitric oxide on the maximal velocity of shortening of a mouse skeletal muscle. Pflugers Arch 1998, 436:906-913.
21. Deconinck N., Rafael J.A., Beckers-Bleukx G., et al. Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse. Neuromuscul Disord 1998, 8:362-370.
22. Moens P., Baatsen P.H., Marechal G. Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil 1993, 14:446-451.
23. De Luca A. Prednisone in dystrophin-deficient Caernorabditis elegans. Neuromuscul Disord 2004;14:696-698 [author reply 698].
24. Segalat L. Drug discovery: here comes the worm. ACS Chem Biol 2006, 1:277-278.
25. Grounds M.D., Radley H.G., Lynch G.S., Nagaraju K., De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 2008, 31:1-19.
26. Su C., Lee C.Y. The mode of neuromuscular blocking action of chlorpromazine. Br J Pharmacol Chemother 1960, 15:88-94.
27. Dhattiwala A.S. The effect of imipramine on isolated skeletal muscle preparations. Indian J Physiol Pharmacol 1977, 21:25-30.
28. Parker J.M., Mendell J.R. Proximal myopathy induced by 5-HT-imipramine simulates Duchenne dystrophy. Nature 1974, 247:103-104.
29. Meltzer H.Y. Skeletal muscle necrosis following membrane-active drugs plus serotonin. J Neurol Sci 1976, 28:41-56.
30. Gumilar F., Arias H.R., Spitzmaul G., Bouzat C. Molecular mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants. Neuropharmacology 2003, 45:964-976.
31. Lopez-Valdes H.E., Garcia-Colunga J. Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake. Mol Psychiatry 2001, 6:511-519.
32. Garcia-Colunga J., Miledi R. Blockage of mouse muscle nicotinic receptors by serotonergic compounds. Exp Physiol 1999, 84:847-864.
33. Zima A.V., Qin J., Fill M., Blatter L.A. Tricyclic antidepressant amitriptyline alters sarcoplasmic reticulum calcium handling in ventricular myocytes. Am J Physiol Heart Circ Physiol 2008, 295:H2008-H2016.
34. 2+ pump. J Bioenerg Biomembr 2000, 32:133-142.
35. Chopra N., Laver D., Davies S.S., Knollmann B.C. Amitriptyline activates cardiac ryanodine channels and causes spontaneous sarcoplasmic reticulum calcium release. Mol Pharmacol 2009, 75:183-195.
36. Hajduch E., Dombrowski L., Darakhshan F., Rencurel F., Marette A., Hundal H.S. Biochemical localisation of the 5-HT2A (serotonin) receptor in rat skeletal muscle. Biochem Biophys Res Commun 1999, 257:369-372.
37. Guillet-Deniau I., Burnol A.F., Girard J. Identification and localization of a skeletal muscle secrotonin 5-HT2A receptor coupled to the Jak/STAT pathway. J Biol Chem 1997, 272:14825-14829.
38. Wappler F., Scholz J., Oppermann S., von Richthofen V., Steinfath M., Schulte am Esch J. Ritanserin attenuates the in vitro effects of the 5-HT2 receptor agonist DOI on skeletal muscles from malignant hyperthermia-susceptible patients. J Clin Anesth 1997, 9:306-311.
39. Thanacoody H.K., Thomas S.H. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev 2005, 24:205-214.
40. + channels. Proc Natl Acad Sci USA 2000, 97:4950-4955.
41. Bannister R.A., Pessah I.N., Beam K.G. The skeletal L-type Ca(2+) current is a major contributor to excitation-coupled Ca(2+) entry. J Gen Physiol 2009, 133:79-91.
42. Phillips MF, Quinlivan R. Calcium antagonists for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; CD004571.
43. Perez-Guerrero C., Suarez J., Herrera M.D., Marhuenda E. Vasodilating effects of tetrazepam in isolated vascular smooth muscles: comparison with cromakalim and diltiazem. Pharmacol Res 1997, 36:237-242.
44. Mokhtarian A., Lefaucheur J.P., Even P.C., Sebille A. Hindlimb immobilization applied to 21-day-old mdx mice prevents the occurrence of muscle degeneration. J Appl Physiol 1999, 86:924-931.
45. Mariol M.C., Martin E., Chambonnier L., Segalat L. Dystrophin-dependent muscle degeneration requires a fully functional contractile machinery to occur in C. elegans. Neuromuscul Disord 2007, 17:56-60.
46. De Luca A., Pierno S., Liantonio A., et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 2003, 304:453-463.
47. Burdi R., Rolland J.F., Fraysse B., et al. Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. J Appl Physiol 2009, 106:1311-1324.
48. Cozzoli A, Rolland JF, Capogrosso RF, et al. Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne Muscular Dystrophy. Neuropathol Appl Neurobiol. doi:10.1111/j.1365-2990.2010.01106.x. [Epub ahead of print]. doi:10.1111/j.1365-2990.2010.01106.x.